###### Key questions

What is already known about this subject?
=========================================

-   Mild cognitive impairment (MCI) is a common comorbidity in atrial fibrillation (AF) and influences a patient's ability to self-care and perform simple daily tasks. Cognitive impairment is becoming increasingly recognised as exerting a powerful and negative impact on the risk profile, management and prognosis of patients with AF.

What does this study add?
=========================

-   Patient outcomes of a cohort of patients with AF were affected by MCI. The presence of MCI in patients with AF undergoing standard postdischarge management did not influence survival or rehospitalisation. However, the benefit of a postdischarge, AF-specific disease management intervention was negatively influenced by the presence of MCI. The risk of death for AF patients with comorbid MCI in the intervention group was increased 5.6-fold, and MCI was the only independent predictor of rehospitalisation during minimum 24-month follow-up, increasing the risk by over threefold. Patients without MCI in the intervention group had significantly less unplanned, all-cause and cardiovascular-specific hospitalisations during follow-up compared with those with MCI.

How might this impact on clinical practice?
===========================================

-   Successful patient care can be influenced by the presence of MCI. Therefore, all older patients with AF should be screened for MCI to allow care to be individualised and tailored accordingly. Adjunctive support for those with MCI may go somewhat towards optimising the health outcomes of these patients.

Introduction {#s1}
============

Atrial fibrillation (AF) is the most common cardiac rhythm disturbance observed in clinical practice. AF is prevalent in 2%--3% of the general population, and more than 70% of individuals with AF are aged 65 years and older.[@R1] Prevalence of AF is rising in parallel to population ageing, improved survival from other clinical conditions that increase the likelihood of AF development and little progress in reducing major significant risk factors such as obesity.[@R1] Multiple complications are the direct result of AF, including thromboembolic events (notably stroke), heart failure, reduced quality-of-life and death.[@R2]

AF is associated with the most common forms of thromboembolism (stroke risk is increased fivefold in patients with AF) and responsible for subtle brain changes due to the occurrence of silent cerebral infarcts, microemboli, microbleeds and cerebral hypoperfusion.[@R4] The result is gradual cognitive dysfunction beginning with mild cognitive impairment (MCI), which markedly influences the ability of patients to self-care and perform simple daily tasks such as taking prescribed medications.[@R9] AF is independently associated with cognitive decline, and patients with AF are at twofold higher risk of cognitive impairment than age-matched patients without AF.[@R10] Cognitive impairment is becoming increasingly recognised as exerting a powerful and negative impact on the risk profile, management and prognosis of patients with AF.[@R12] Higher rates of morbidity, symptom severity, healthcare utilisation and mortality resulting from the negative impact of cognitive impairment have been observed in older individuals (some with heart failure and other cardiovascular conditions)[@R13] and the same is likely to be observed in AF populations. AF patients with cognitive impairment have poorer anticoagulation adherence, more frequent cardiovascular events and demonstrate greater functional impairment compared with those without cognitive impairment.[@R12] Additionally, patients with MCI are vulnerable to mood disorders including depression[@R17] with psychosocial and cognitive comorbidities clustering frequently in patients with AF.[@R14] The resulting psychosocial and cognitive multimorbidity exerts a powerful and negative effect on AF-specific quality of life.[@R14]

With the continued evolution of individualised care to optimise AF management,[@R18] it is imperative to understand the influence of cognitive impairment on the effectiveness of care for patients with AF. Therefore, we aimed to investigate the influence of MCI on the outcomes (namely mortality, days alive and out-of-hospital and rehospitalisations) of patients hospitalised as a result of AF. Furthermore, we aimed to examine the impact of MCI on the outcomes of patients participating in an AF-specific disease management programme compared with those undergoing standard postdischarge management.

Methods {#s2}
=======

Study setting {#s2a}
-------------

Details of the Standard versus Atrial Fibrillation spEcific managemenT strategY (SAFETY) Trial protocol[@R19] and primary composite endpoint outcomes of death or unplanned rehospitalisation due to any cause[@R20] have been reported previously. Briefly, 335 inpatients (52% male) from three tertiary referral hospitals in Australia with a diagnosis of chronic forms of AF (recurrent paroxysmal, persistent or permanent AF) were randomly assigned into the study. Participants were randomised (via a computer-generated protocol and using block groups) to either standard management (SM; n=167) or an AF-specific home-based management intervention (HBI; n=168) aimed at reducing morbidity and mortality following hospital discharge. Nurse-led clinic visits were conducted at 12 and 24 months for follow-up assessment of surviving patients, with comprehensive details of all deaths and rehospitalisations collected.

The SAFETY Trial was prospectively registered with the Australian New Zealand Clinical Trials Registry (ANZCTRN: 12610000221055) and was Consolidated Standards of Reporting Trials compliant with outcomes reported appropriately for a pragmatic trial comparing the efficacy of two non-pharmacological health interventions.[@R21] Written informed consent was obtained from each study participant prior to any study procedure being conducted. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki.

Participants {#s2b}
------------

Using a systematic screening programme to identify eligible participants, inpatients were approached for recruitment if they were aged 45 years or older, had a documented diagnosis of a chronic form of AF (persistent or permanent AF), would be living independently in the community or their own home postdischarge and were able and willing to provide written informed consent to participate. Those who had a primary diagnosis of valvular heart disease, had a transient form of AF, were scheduled for catheter ablation and/or had concurrent heart failure (confirmed on echocardiography (including screening for evidence of diastolic heart failure) and defined as displaying New York Heart Association class III--IV symptoms with a documented left ventricular ejection fraction of less than 45%) were excluded from participation. Also excluded from participation were those who had a documented diagnosis of cognitive impairment, delirium or dementia and those who were not proficient in understanding or conversing in English (ie, those unable to provide informed consent).

Baseline cohort profiling {#s2c}
-------------------------

Comprehensive baseline profiling was conducted in all participants during index hospitalisation. Data were collected on sociodemographic status, past medical history (including AF-specific details), inhospital and planned postdischarge management, prescribed therapeutics, thromboembolic risk (calculated by the CHA~2~DS~2~-VASc score[@R22]), comorbid conditions including calculation of an age-adjusted Charlson Comorbidity Index score[@R23] and cognitive status (determined by the Montreal Cognitive Assessment (MoCA) tool[@R24]). The MoCA is a 10 min, 30-item screening tool for MCI. A cut-off score of 26 (range 0--30) has been shown to have high sensitivity (0.90) and specificity (0.87) for detecting MCI.[@R24] To account for differences in education attained, one point is added to the total score for those with ≤12 years of formal education (education level-corrected scores of below 26 are considered as being cognitively 'impaired').[@R24] The MoCA was administered to n=260 of the total cohort of 335 patients. Patients who did not undertake the MoCA were those who were physically unable to do so (eg, due to vision disturbance) and those from non-English speaking backgrounds who may have been proficient in English but for whom the MoCA has not been validated.

Study intervention {#s2d}
------------------

The study intervention involved proactive patient management to optimise gold standard pharmacological and non-pharmacological management according to guidelines. Structured postdischarge care consisted of an initial home visit conducted by an intervention nurse at 7--14 days postdischarge and a combination of telephone follow-up and repeat home visits. The initial home visit, which involved a comprehensive assessment of each patient, was performed including evaluation of medication adherence, self-care, disease knowledge and clinical status (blood pressure, international normalised ratio where appropriate, current symptoms and heart rate and rhythm (12-lead ECG)). A postvisit needs assessment of each participant was conducted including risk stratification based on visit findings and determination of level of intervention required to maintain (or achieve) clinical stability during follow-up. Clinic reviews were conducted at 12 and 24 months postdischarge. Components of the individualised management were specifically focused on AF and included advanced clinical assessment (including the use of Holter monitoring), a review of social circumstances, education, review of medications and treatment plan according to gold standards, identification of barriers to self-care and communication with or referral to other healthcare providers and community services.

Statistical analyses {#s2e}
--------------------

Descriptive data are presented as mean (with SD) or median (with IQR) for continuous variables or as a proportion (%) for categorical variables. Between-group comparisons were conducted with Student's t-test, χ^2^ test or Mann-Whitney U test where appropriate.

We performed Kaplan-Meier survival analyses in the overall cohort and in the SM and HBI groups separately to assess survival from all-cause mortality and time to the primary endpoint of mortality and unplanned readmission (measured as days alive and out-of-hospital) in participants classified as having MCI (MoCA scores \<26/30) versus those of normal cognition (MoCA scores ≥26/30). Group comparisons were performed with a log-rank test. Mean survival time (with 95% CIs) was calculated for each respective group. As the number of potential covariates was large relative to the sample size, only covariates that were empirically related to outcomes were included. Covariates were identified using multiple logistic regression with backwards, stepwise selection for: all-cause mortality, inclusion in the lower quartile of days alive and out-of-hospital (≤763 days), all-cause hospital admission and hospital admission due to cardiovascular disease (CVD). All multiple logistic regression models included sociodemographic (age and gender), lifestyle (current smoking), medical history/status (MCI, hypertension, cerebrovascular disease and type 2 diabetes) and treatment factors (rate/rhythm control, beta blocker, calcium channel blocker, ACE inhibitor, angiotensin II receptor blocker, digoxin and warfarin prescription), and all models were stratified by group of randomisation (SM vs HBI). MCI was initially entered into all statistical models as a binary variable ('Yes' vs 'No'). To test the interaction of randomisation group with MCI status, we replaced MCI in the overall regression models with a four-group variable (noMCI-HBI, MCI-HBI, noMCI-SM and MCI-SM). All data were analysed using SPSS V.22.0. A probability value of P\<0.05 (two sided) was considered statistically significant.

Results {#s3}
=======

Baseline profile {#s3a}
----------------

Baseline characteristics of SAFETY participants stratified by randomisation group and MCI are presented in [table 1](#T1){ref-type="table"}. Of the total cohort, 65% demonstrated MCI on screening (n=89 (34%) in SM and n=80 (31%) in HBI). Overall, this cohort included older patients (mean age 72±11 years) at high thromboembolic and clinical risk (mean CHA~2~DS~2~-VASc score 3.6±1.8) and suffering from multimorbidity (mean Charlson Comorbidity Index 5.0±2.5). Within the SM group, those with MCI were significantly older (mean age 74 years vs 68 years, respectively), at higher thromboembolic risk (mean CHA~2~DS~2~-VASc score 4.0 vs 2.8, respectively) and suffering from significantly more comorbidity (mean Charlson Comorbidity Index score 5.6 vs 4.3, respectively) than those without MCI. The same patterns were identified within the HBI group. Although, in addition, significantly less participants with MCI obtained tertiary-level education (24% vs 44%, respectively) and significantly more suffered from vascular disease and were prescribed digoxin therapy compared with those without MCI (10% vs 0% and 44% vs 23%, respectively).

###### 

Baseline characteristics of the SAFETY cohort according to randomisation group and cognitive status

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                         All\         Standard management\   P value     Home-based intervention\   P value                 
                                                         (n=260)      (n=132)                            (n=128)                                            
  ------------------------------------------------------ ------------ ---------------------- ----------- -------------------------- ----------- ----------- -------
  Sociodemographic profile                                                                                                                                  

   Mean age (years)                                      72±11        74±10                  68±13       0.008                      73±10       69±11       0.029

   Male, n (%)                                           137 (52.7)   46 (51.7)              25 (58.1)   0.577                      43 (53.8)   23 (47.9)   0.585

   Living alone, n (%)                                   110 (42.3)   37 (41.6)              15 (34.9)   0.569                      35 (43.8)   23 (47.9)   0.715

   Tertiary level education, n (%)\*                     83 (32.3)    29 (33.0)              14 (33.3)   1.000                      19 (24.1)   21 (43.8)   0.030

  AF-specific profile                                                                                                                                       

   Persistent AF, n (%)                                  234 (90.0)   82 (92.1)              39 (90.7)   0.748                      71 (88.8)   42 (87.5)   1.000

   Permanent AF, n (%)                                   26 (10.0)    7 (7.9)                4 (9.3)     0.748                      9 (11.3)    6 (12.5)    1.000

   Mean CHA~2~DS~2~-VASc score†                          3.6±1.8      4.0±1.6                2.8±1.8     \<0.001                    3.9±1.8     3.1±1.5     0.013

   Asymptomatic AF, n (%)                                41 (15.8)    12 (13.5)              7 (16.3)    0.792                      10 (12.5)   12 (25.0)   0.091

   Rate control, n (%)                                   177 (68.1)   61 (68.5)              26 (60.5)   0.434                      61 (76.3)   29 (60.4)   0.073

   Rhythm control, n (%)                                 83 (31.9)    28 (31.5)              17 (39.5)   0.434                      19 (23.8)   19 (39.6)   0.073

  Risk factor profile                                                                                                                                       

   Current smoker, n (%)‡                                36 (14.0)    13 (14.6)              7 (16.7)    0.797                      11 (13.9)   5 (10.4)    0.784

   'High risk' alcohol intake, n (%)§¶                   43 (17.2)    15 (17.0)              6 (14.6)    0.803                      14 (18.7)   8 (17.4)    1.000

   Moderate exercise, n (%)\*\*††                        121 (46.7)   42 (47.2)              21 (48.8)   1.000                      34 (43.0)   24 (50.0)   0.468

   Mean heart rate (bpm)                                 98±34        75±15                  73±15       0.617                      74±15       74±21       0.833

   Systolic BP (mm Hg)                                   126±18       126±19                 124±15      0.659                      128±19      124±19      0.264

   Diastolic BP (mm Hg)                                  70±12        70±12                  71±10       0.624                      71±13       69±12       0.374

   Mean total serum cholesterol (mmol/L)                 4.2±1.1      3.9±1.0                4.6±1.2     0.007                      4.2±1.1     4.1±1.2     0.589

   Mean body mass index (kg/m^2^)                        29.6±6.7     28.6±5.4               30.7±7.9    0.131                      29.7±7.5    29.9±6.3    0.873

  Comorbidity profile                                                                                                                                       

   Hypertension, n (%)                                   188 (72.3)   66 (74.2)              25 (58.1)   0.073                      62 (77.5)   35 (72.9)   0.671

   Coronary artery disease, n (%)                        84 (32.3)    32 (36.0)              11 (25.6)   0.322                      29 (36.3)   12 (25.0)   0.241

   Type 2 diabetes, n (%)                                67 (25.8)    22 (24.7)              8 (18.6)    0.510                      28 (35.0)   9 (18.8)    0.069

   Prior cerebrovascular event, n (%)                    41 (15.8)    17 (19.1)              4 (9.3)     0.206                      14 (17.5)   6 (12.5)    0.616

   Chronic obstructive pulmonary disease, n (%)          46 (17.7)    18 (20.2)              8 (18.6)    1.000                      14 (17.5)   6 (12.5)    0.616

   Vascular disease, n (%)                               15 (5.8)     5 (5.6)                2 (4.7)     1.000                      8 (10.0)    0 (0.0)     0.025

   Depression, n (%)‡                                    60 (23.3)    21 (23.6)              8 (18.6)    0.655                      21 (26.9)   10 (20.8)   0.525

   Renal impairment (eGFR \<60 mL/min/1.73^2^), n (%)‡   97 (37.6)    39 (43.8)              15 (34.9)   0.351                      30 (37.5)   13 (28.3)   0.333

   Charlson Comorbidity Index                            5.0±2.5      5.6±2.5                4.3±2.6     0.007                      5.2±2.5     4.1±2.3     0.016

  Treatment profile                                                                                                                                         

   Beta blocker, n (%)                                   130 (50.0)   42 (47.2)              20 (46.5)   1.000                      45 (56.3)   23 (47.9)   0.368

   Digoxin, n (%)                                        92 (35.4)    34 (38.2)              12 (27.9)   0.330                      35 (43.8)   11 (22.9)   0.022

   Antiarrhythmic (%)                                    69 (26.5)    26 (29.2)              12 (27.9)   1.000                      15 (18.8)   16 (33.3)   0.088

   Diuretic, n (%)                                       109 (41.9)   36 (40.4)              18 (41.9)   1.000                      38 (47.5)   17 (35.4)   0.201

   Warfarin, n (%)                                       141 (54.2)   51 (57.3)              24 (55.8)   1.000                      40 (50.0)   26 (54.2)   0.716

   Aspirin, n (%)                                        126 (48.5)   45 (50.6)              17 (39.5)   0.267                      42 (52.5)   22 (45.8)   0.584
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Assessed in n=257 patients.

†CHA~2~DS~2~-VASc score definition: C=*congestive heart failure/LV dysfunction* (1 point), H=*hypertension* (even if treated; 1 point), A~2~=*age ≥75 years* (2 points), D=*diabetes* mellitus (1 point), S~2~=*stroke/systemic embolism/transient ischaemic attack* (2 points), V=*vascular* disease (1 point), A=*age 65--74 years* (1 point), Sc=*sex* category (female sex; 1 point), for the current research, the CHA~2~DS~2~-VASc score is scored from 0 to 8 (not 0--9 as is the norm) due to the exclusion of patients with chronic heart failure.

‡Assessed in n=258 patients.

§Assessed in n=250 patients.

¶Defined as consumption of \>2 standard drinks on any occasion (on average).

\*\*Meeting recommendation of \>150 min per week of moderate exercise.

††Assessed in n=259 patients.

AF, atrial fibrillation; BP, blood pressure; BMI, body mass index; bpm, beats per minute; eGFR, estimated glomerular filtration rate; MCI, mild cognitive impairment.

Survival {#s3b}
--------

### All-cause mortality {#s3b1}

[Figure 1](#F1){ref-type="fig"} shows the unadjusted survival curves of participants with and without MCI in the overall cohort ([figure 1A](#F1){ref-type="fig"}) and in the SM ([figure 1B](#F1){ref-type="fig"}) and HBI ([figure 1C](#F1){ref-type="fig"}) groups separately. Over a mean follow-up of 879±299 days, 40 individuals died overall (15.4%) including 31/169 participants (18.3%) with MCI and 9/91 (9.9%) without MCI. Mean survival time in these groups was 1209 days (95% CI 1149 to 1269 days) and 1255 days (95% CI 1187 to 1324) days, respectively. Within the SM group, over a mean follow-up of 874±289 days, 24 individuals died (18.2%) including 17/89 participants (19.1%) with MCI and 7/43 (16.3%) without MCI. Mean survival time in these groups was 1206 days (95% CI 1129 to 1284 days) and 1187 days (95% CI 1068 to 1306 days), respectively. Within the HBI group, over a mean follow-up of 884±310 days, 16 individuals died (12.5%) including 14/80 participants (17.5%) with MCI and 2/48 (4.2%) without MCI. Mean survival time in these groups was 1206 days (95% CI 1116 to 1297) days and 1315 (95% CI 1248 to 1382) days, respectively. [Figure 1A,B](#F1){ref-type="fig"} demonstrates no significant difference in mortality between those with or without MCI in the cohort overall (log rank P=0.089) and in the SM group (log rank P=0.740). However, in the HBI group ([figure 1C](#F1){ref-type="fig"}), a significant difference in survival was demonstrated with MCI sufferers experiencing worse survival than those without MCI (log-rank P=0.036). Multiple logistic regression performed on the cohort overall revealed that increasing age (OR 1.17 (95% CI 1.10 to 1.24), P\<0.001) and current smoking (OR 4.97 (95% CI 1.63 to 15.13), P=0.005) were predictive of all-cause mortality during study follow-up ([table 2](#T2){ref-type="table"}). The same predictors were identified on analysis in the SM group. In addition to increasing age, participants in the HBI group were over 5.5 times more likely to die if they had MCI (OR 5.57 (95% CI 1.10 to 28.1), P=0.038). No interaction between randomisation group and MCI status was identified for all-cause mortality (data not shown).

![Unadjusted survival from all-cause mortality of participants with and without MCI in (A) overall cohort, (B) standard management cohort and (C) home-based intervention cohort. MCI, mild cognitive impairment.](openhrt-2017-000755f01){#F1}

###### 

Independent correlates of survival (all-cause mortality and event-free survival via lower quartile of days alive and out-of-hospital) overall and in HBI and SM groups separately

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               All-cause mortality\   Lower quartile of days alive and out-of-hospital\                                                                
                               OR (95% CI)            OR (95% CI)                                                                                                      
  ---------------------------- ---------------------- --------------------------------------------------- ------------------ -------------------- -------------------- ------------------
  Sociodemographic profile                                                                                                                                             

   Age (years)                 1.17\                  1.20\                                               1.08\              1.09\                1.09\                1.08\
                               (1.10 to 1.24)\*\*     (1.10 to 1.31)\*\*                                  (1.00 to 1.16)\*   (1.05 to 1.13)\*\*   (1.04 to 1.14)\*\*   (1.02 to 1.13)\*

  Risk factor profile                                                                                                                                                  

   Mild cognitive impairment   --                     --                                                  5.57\              2.04\                --                   3.48\
                                                                                                          (1.10 to 28.1)\*   (0.98 to 4.25)                            (1.06 to 11.4)\*

   Current smoker†             4.97\                  9.63\                                                                  2.54\                5.07\                --
                               (1.63 to 15.13)\*      (2.25 to 41.21)\*                                                      (1.04 to 6.19)\*     (1.62 to 15.91)\*    

  Comorbidity profile                                                                                                                                                  

   Type 2 diabetes             2.23\                  --                                                  --                 2.04\                --                   2.97\
                               (0.96 to 5.19)                                                                                (1.04 to 4.00)\*                          (1.34 to 7.77)\*

  Treatment profile                                                                                                                                                    

   Digoxin                     --                     --                                                  0.08\              --                   --                   --
                                                                                                          (0.01 to 0.69)\*                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P\<0.05.

\*\*P\<0.001.

†Assessed in n=258 patients.

HBI, home-based intervention; SM, standard management.

### Event-free survival (days alive and out-of-hospital) {#s3b2}

[Figure 2](#F2){ref-type="fig"} shows the unadjusted Kaplan-Meier curves for the primary endpoint (time to mortality and unplanned readmission) of participants with and without MCI in the overall cohort ([figure 2A](#F2){ref-type="fig"}) and in the SM ([figure 2B](#F2){ref-type="fig"}) and HBI ([figure 2C](#F2){ref-type="fig"}) groups separately. During follow-up, 206 individuals died or had an unplanned readmission overall (79.2%) including 145/169 participants (85.8%) with MCI and 61/91 (67.0%) without MCI. Mean number of days alive and out-of-hospital in these groups was 411 days (95% CI 344 to 477) and 554 days (95% CI 446 to 663) days, respectively. Within the SM group, 110 individuals died or had an unplanned readmission (83.3%) including 77/89 participants (86.5%) with MCI and 33/43 (76.7%) without MCI. Mean number of days alive and out-of-hospital in these groups was 422 days (95% CI 334 to 510) and 498 days (95% CI 372 to 624), respectively. Within the HBI group, 96 individuals died or had an unplanned readmission (75.0%) including 68/80 participants (85.0%) with MCI and 28/48 (58.3%) without MCI. Mean number of days alive and out-of-hospital in these groups was 392 days (95% CI 294 to 490) and 602 days (95% CI 435 to 769), respectively. No significant difference in time to the primary endpoint was demonstrated in the SM group between those with or without MCI ([figure 2B](#F2){ref-type="fig"}; log rank P=0.263). However, in the cohort overall and in the HBI group ([figure 2A,C](#F2){ref-type="fig"}), a significant difference in the number of days alive and out-of-hospital was demonstrated with MCI sufferers experiencing death or unplanned readmission earlier than those without MCI (log-rank P=0.012 and P=0.022, respectively).

![Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort and (C) home-based intervention cohort. MCI, mild cognitive impairment.](openhrt-2017-000755f02){#F2}

On adjusted analyses ([table 2](#T2){ref-type="table"}) in the overall cohort, age (OR 1.09 (95% CI 1.05 to 1.13), P\<0.001), current smoking (OR 2.54 (95% CI 1.04 to 6.19), P=0.040) and comorbid type 2 diabetes (OR 2.04 (95% CI 1.04 to 4.00), P=0.039) were significantly predictive of experiencing the shortest duration of event-free survival (ie, inclusion in the lower quartile of days alive and out-of-hospital). Only age and current smoking were significantly predictive of the same in the SM group (OR 1.09 (95% CI 1.04 to 1.14), P\<0.001 and OR 5.07 (95% CI 1.62 to 15.91), P=0.005, respectively). MCI was significantly associated with patients having fewer days alive and out-of-hospital in the HBI group (OR 3.48 (95% CI 1.06 to 11.4), P=0.039) in addition to increasing age and comorbid type 2 diabetes ([table 2](#T2){ref-type="table"}). Online [supplementary table 1](#SP1){ref-type="supplementary-material"} demonstrates the results of analyses conducted to understand the interaction between randomisation group and MCI status. Compared with individuals in the HBI group with no MCI, the odds of experiencing the shortest duration of event-free survival for those with MCI in the HBI group were more than tripled and for those with MCI in the SM group, the odds were almost quadrupled.
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Hospital readmissions and stay {#s3c}
------------------------------

### All-cause rehospitalisation {#s3c1}

[Table 3](#T3){ref-type="table"} demonstrates the results of multiple logistic regression analyses identifying independent correlates of all-cause rehospitalisation. In the overall cohort, MCI increased the risk of rehospitalisation due to any cause by over three times during follow-up (OR 3.16 (95% CI 1.46 to 6.84), P=0.003). Smoking and type 2 diabetes significantly decreased the risk of all-cause rehospitalisation (OR 0.39 (95% CI 0.15 to 0.99), P=0.048 and OR 0.36 (95% CI 0.15 to 0.83), P=0.017, respectively). In the SM group, risk of all-cause rehospitalisation was significantly increased with increasing age (OR 1.07 (95% CI 1.02 to 1.34), P=0.012) and, again, significantly reduced in smokers and those with type 2 diabetes. The only independent correlate of all-cause rehospitalisation in the HBI group was MCI, which more than tripled the risk of all-cause rehospitalisation (OR 3.30 (95% CI 1.25 to 8.69), P=0.016). Online [supplementary table 1](#SP1){ref-type="supplementary-material"} also demonstrates that compared with individuals in the HBI group with no MCI, the odds of experiencing all-cause rehospitalisation for those with MCI in the HBI group were almost quadrupled, and for those with MCI in the SM group, the odds were increased fivefold.

###### 

Independent correlates of rehospitalisation (all cause and CVD related) overall and in HBI and SM groups separately

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     All-cause rehospitalisation\   CVD-related rehospitalisation\                                                            
                                     OR (95% CI)                    OR (95% CI)                                                                               
  ---------------------------------- ------------------------------ -------------------------------- ------------------ ------------------ ------------------ ------------------
  Sociodemographic profile                                                                                                                                    

   Age (years)                       --                             1.07\                            --                 --                 --                 --
                                                                    (1.02 to 1.34)\*                                                                          

   Sex (female/male)                 --                             --                               --                 --                 2.10\              --
                                                                                                                                           (0.95 to 4.61)     

  Risk factor profile                                                                                                                                         

   Mild cognitive impairment         3.16\                          --                               3.30\              1.60\              --                 2.35\
                                     (1.46 to 6.84)\*                                                (1.25 to 8.69)\*   (0.94 to 2.74)                        (1.12 to 4.91)\*

   Current smoker†                   0.39\                          0.15\                            --                 --                 --                 --
                                     (0.15 to 0.99)\*               (0.03 to 0.66)\*                                                                          

  Comorbidity profile                                                                                                                                         

   Type 2 diabetes                   0.36\                          0.18\                            --                 --                 --                 --
                                     (0.15 to 0.83)\*               (0.04 to 0.79)\*                                                                          

  Treatment profile                                                                                                                                           

   Calcium channel blocker           --                             --                               --                 --                 2.57\              --
                                                                                                                                           (0.87 to 7.63)     

   Angiotensin II receptor blocker   2.50\                          8.82\                            --                 --                 --                 --
                                     (0.89 to 7.04)                 (0.84 to 92.54)                                                                           

   Digoxin                           --                             --                               --                 1.84\              2.58\              --
                                                                                                                        (1.05 to 3.24)\*   (1.08 to 6.16)\*   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P\<0.05.

\*\*P\<0.001.

†Assessed in n=258 patients.

CVD, cardiovascular disease; HBI, home based intervention; SM, standard management.

### CVD-related rehospitalisation {#s3c2}

Digoxin significantly increased the risk of CVD-related rehospitalisation in the cohort overall and in the SM group. In a similar pattern to all-cause rehospitalisation, the only independent correlate of CVD-related rehospitalisation in the HBI group was MCI ([table 3](#T3){ref-type="table"}). Those with MCI were over twofold more likely to be hospitalised due to CVD during follow-up (OR 2.35 (95% CI 1.12 to 4.91), P=0.024). No interaction between randomisation group and MCI status was identified for CVD-related rehospitalisation (data not shown).

Discussion {#s4}
==========

In a typically older and clinically complex AF patient population, we found that the health outcomes of patients undergoing a nurse-led, AF-specific disease management intervention were negatively impacted by the presence of MCI. Overall, MCI influenced the number of days spent alive and out-of-hospital and all-cause rehospitalisation of the cohort during follow-up (but not mortality or CVD-related hospitalisation) and did not influence any outcomes for those in the SM group. However, significantly worse outcomes were experienced by those in the HBI group who had MCI. Survival was significantly influenced by MCI; these individuals were at over 5.5 times the risk of dying. This diminished survival was driven, at least in part, by reduced event-free survival; those with MCI in the HBI group were 3.5 times more likely to experience the shortest duration of event-free survival during follow-up. Furthermore, MCI was the only independent correlate of all-cause and CVD-related rehospitalisation in the HBI group. When the interaction between randomisation group and MCI status was analysed, significant differences in event-free survival and all-cause rehospitalisation were demonstrated between those with and without MCI but not between HBI and SM.

To our knowledge, this is the first study to demonstrate a significant disadvantage to health outcomes (survival and rehospitalisations) associated with the implementation of a disease management intervention in those with AF and MCI. This phenomenon has, however, been identified previously in the context of heart failure. Findings of a study comparing a heart failure-specific disease management intervention with SM demonstrated that MCI was of prognostic importance even when a disease-specific intervention was applied.[@R25] Similarly, a study investigating the impact of a self-care training intervention to reduce hospital readmissions in heart failure patients with MCI found that despite increasing patient knowledge, readmission rates were not reduced.[@R26] Conversely, in a study conducted by Ketterer and colleagues, a heart failure-specific disease management intervention implemented in patients with comorbid MCI resulted in a 30% reduction in early readmission compared with a control group.[@R27] In this study, those with MCI were provided additional support including conducting a discussion with the patient by all members of their treatment team about the effect of cognitive impairment on adherence to their complex medication regimens, provision of cognitive impairment-specific psychoeducation and the involvement of family members to act as healthcare collaborators.[@R27]

HBI appears highly effective for patients without MCI but has relatively little benefit in those with MCI. Given that a potent effect of MCI was identified in the HBI group only, it is possible that a disease-specific intervention of this design is too confusing for those who already have difficulty with information processing and executive functioning. It may not be appropriate to apply such a comprehensive (and potentially complex) intervention in this patient group. It is also possible that application of information provided in this format is confronting and may trigger health-related anxiety for those with MCI. The result may be a lack of confidence in self-management, reduced self-care and declining clinical stability. The reasons behind the lack of effectiveness in this patient group is likely to be multifactorial, but an intervention that is not tailored towards addressing cognitive dysfunction potentially should not be implemented. For the intervention to be effective in patients with AF and comorbid MCI, integration with healthcare systems (such as psychology and nursing organisations) and a programme design that explicitly caters for cognitively impaired patients is critical. This may also involve care givers more prominently.

Despite the potential for the findings of this work to be considered as part of a 'generic' phenomenon (given it is also seen in heart failure), the high prevalence of MCI in patients with AF means that these individuals should still be considered at high risk for an 'adverse' reaction to AF (particularly in older individuals) and management must be tailored in response. Therefore, the findings of this study carry substantial clinical significance and support the need for engaging in patient-centred care and individualised, integrated management for those with AF. Evidence-based care of AF patients that maximises effectiveness, safety and efficiency is the ultimate goal and, therefore, enhanced recognition of cognitive impairment and more proactive patient management is necessary. In addition, screening for MCI should become routine practice for patients with AF with results used to inform the relevance, application and content of AF-specific disease management.

Limitations {#s4a}
-----------

There exist some study limitations that require comment. First, we employed only one method for MCI detection, although the MoCA is a quick and easy tool that demonstrates enhanced sensitivity to early impairment, unlike other screening tools.[@R28] Additionally, the entire SAFETY Trial cohort was not screened for MCI due to issues with vision and not originating from an English-speaking background; selection bias may have been introduced as a result causing underestimation or overestimation of MCI in this cohort and findings that are not representative. The number of events was also relatively small in the cohort potentially affecting the accuracy and/or generalisability of results. Generalisability may also be affected due to this study being conducted within the Australian urban context with the inclusion of participants principally of European descent. Furthermore, this was a selected population of patients with AF who did not have heart failure, a common comorbidity. Age, thromboembolic risk (CHA~2~DS~2~-VASc score) and severity of comorbidity (Charlson Comorbidity Index) was significantly different at baseline between those with and without MCI in both study groups, although these factors were adjusted for in all statistical models. Finally, we acknowledge that differences detected in this study may have arisen due to multiple testing and type I error. However, this was a hypothesis-driven statistical analysis (rather than exploratory) and is consistent with previous findings in heart failure cohorts. Using a more conservative statistical approach (eg, applying Bonferonni correction) would have reduced study power, which needs to be conserved given the number of events observed and stratification of the cohort into those with and without MCI. Therefore, the statistical analyses conducted were appropriate and consistent with the data.

Conclusions {#s5}
===========

We found that the benefit of a home-based, AF-specific disease management intervention for patients with AF was affected by patient cognitive function. MCI was associated with increased mortality and healthcare usage of patients with chronic forms of AF. Therefore, routine screening and detection is critical to direct patient care and optimise management. Future research is required to: (1) further investigate the influence of MCI particularly on the self-care and self-management of patients with AF; (2) further elucidate the relationship between MCI and different forms of AF patient management; and (3) assess the effectiveness of an AF-specific disease management intervention that includes adjunctive support for patients with MCI.
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